Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(8 years from now) | |
US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(15 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(9 years from now) | |
US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 17, 2027 |
NCE-1 date: February, 2026
Market Authorisation Date: 17 February, 2022
Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic